2024 Update on the Multimodality Management of Bladder and Kidney Cancer — On Demand

This course, originally presented live from November 21–23, 2024, showcases the latest advancements in the multidisciplinary management of bladder and kidney cancers. It equips learners with the knowledge to provide cutting-edge care for patients across all stages of these diseases, covering topics such as:

— Management strategies for localized kidney cancer and non-muscle invasive bladder cancer
— Neoadjuvant and adjuvant systemic therapies for muscle-invasive bladder cancer
— Treatment paradigms for advanced kidney cancer and optimal surgical approaches for high-risk cases
— Advanced imaging modalities for kidney cancer
— The role of intraoperative and SBRT techniques for treating bladder and kidney cancers
— A review of hereditary kidney cancer syndromes

The keynote presentation details new standards in managing advanced urothelial cancer. Updated trial data is presented, detailing recent changes in the standard of care for advanced urothelial cancer, focusing on combination therapies that include novel antibody-drug conjugates and checkpoint inhibitors. Additionally, video sessions highlight surgical techniques for urinary diversion, utilizing both open and robotic methods, as well as radical nephrectomy with thrombectomy.

For more information about what's available in this on-demand program, including a detailed list of presentations, view the brochure from the live course.

1. Present a multidisciplinary approach to the management of bladder and kidney cancer including surgical, medical, and radiation therapies
2. Disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer
3. Integrate new therapeutics into the treatment of localized, locally advanced, and metastatic bladder and kidney cancers

Access to the course content requires registration. Once registered, all materials, including relevant financial disclosures and instructions for claiming credit, are located under the 'Course Content' tab. This on-demand program is available for purchase until June 30, 2025. For those that purchase this on demand, access to the content, as well as the opportunity to claim credit, is available through September 30, 2025. 

On Demand Fees
— Physicians (MDs, PhDs, and DOs): $600
— Advanced Practice Providers: $450
— Residents, and Fellows: $400
— Nurses and Other Healthcare Providers: $350
— MSK Employees: Complimentary

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information and to submit a request. Please note that after your payment has been processed, no further promotional discounts or adjustments will be made to your registration.

This Memorial Sloan Kettering Continuing Medical Education on demand program is non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 14.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.00 credits/points in the following certification programs:

— Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification Assessment Recognition Program; and
— Lifelong Learning (Part II) credits for the American Board of Pathology (ABPath) Continuing Certification program; and
— Accredited CME and Self-Assessment credits for the American Board of Surgery (ABS) Continuous Certification program; and

MOC/CC points will be reported to your board within 45 days upon completion of the course.

Recorded/Review Date: November 21-23, 2024 | Original Release Date: December 16, 2024 | Termination Date: September 30, 2025

MSK Course Directors 

Bernard H. Bochner, MD, FACS
Sir Murray F. Brennan Chair in Surgery
Attending, Urology Service
Department of Surgery

Jonathan E. Rosenberg, MD
Chief Attending, Genitourinary Oncology Service
Enno W. Ercklentz, Jr. Chair
Department of Medicine 

MSK Course Planners 

Maria Carlo, MD
Assistant Attending, Genitourinary Oncology Service
Department of Medicine 

Muhammad Hassan Alkazemi, MD
Urologic Surgical Oncology Fellow

Sahil Doshi, MD
Medical Oncology  Fellow

Daniel Gorovets, MD
Assistant Attending, External Beam Radiotherapy Service
Department of Radiation Oncology

Aditi Gupta, MD
Hematology Oncology Fellow 

A. Ari Hakimi, MD
Associate Attending, Urology Service 
Department of Surgery 

Gopa Iyer, MD
Section Head, Bladder Cancer
Associate Attending, Genitourinary Oncology Service 
Department of Medicine 

Marisa A. Kollmeier, MD
Chief, Brachytherapy Service
Program Director, Brachytherapy Fellowship
Attending, External Beam Radiotherapy Service
Department of Radiation Oncology

Vashti Livingston, BS, MS, CWOCN
Clinical Nurse, Urology Outpatient Center

Robert J. Motzer, MD
Section Head, Kidney Cancer, Genitourinary Oncology Service
Jack and Dorothy Byrne Chair in Clinical Oncology
Attending, Genitourinary Oncology Service
Department of Medicine 

Eugene Pietzak, MD
Assistant Attending, Urology Service 
Department of Surgery 

Martin H. Voss, MD
Associate Attending; Clinical Director, Genitourinary Medical Oncology Service
Department of Medicine 

Michal Sternschuss, MD
Genitourinary Oncology Fellow

Invited Faculty 

Phillip M. Pierorazio, MD
Chief, Section of Urology, Penn Presbyterian Medical Center 
Professor of Surgery, University of Pennsylvania

MSK Faculty 

David H. Aggen, MD, PhD
Assistant Attending, Genitourinary Oncology Service
Department of Medicine 

Ziad Bakouny, MD, MSc
Medical Oncology Fellow

Eugene K. Cha, MD
Associate Attending, Urology Service 
Department of Surgery 

Jonathan A. Coleman, MD
David H. Koch Chair
Attending, Urology Service 
Department of Surgery

Mark Dawidek, MD
Urologic Oncology Fellow

Timothy F. Donahue, MD
Associate Attending, Urology Service 
Department of Surgery 

S. Machele Donat, MD, FACS
Attending, Urology Service 
Department of Surgery 

Darren R. Feldman, MD
Section Head, Germ Cell Cancer
Associate Attending, Genitourinary Oncology Service
Department of Medicine 

Samuel A. Funt, MD
Assistant Attending, Genitourinary Oncology Service
Department of Medicine

Alvin C. Goh, MD
Director, Robotic Urologic Surgery Technology and Education
Associate Attending, Urology Service 
Department of Surgery 

Allison Gordon, MD
Assistant Attending, Dermatology Service
Department of Medicine 

Ritesh R. Kotecha, MD
Assistant Attending, Genitourinary Oncology Service
Department of Medicine 

Daniel E. Lage, MD, MBA, MSc
Assistant Attending, Genitourinary Oncology Service
Department of Medicine 

Alicia Latham, MD, MS
Medical Director, MSK-CATCH 
Assistant Attending, Clinical Genetics Service
Department of Medicine

Sunny Nalavenkat, MD
Urologic Oncology Fellow

Himanshu Nagar, MD, MS
Director, Genitourinary Program
Associate Attending
Department of Radiation Oncology

Neeta Pandit-Taskar, MD
Director, Nuclear Medicine Pediatrics
Attending, Molecular Imaging and Therapy Service
Department of Radiology

Fourat Ridouani, MD
Assistant Attending, Interventional Radiology Service 
Department of Radiology 

Paul Russo, MD, FACS
Attending, Urology Service
Department of Surgery 

Neil J. Shah, MBBS
Assistant Attending, Solid Tumor Genitourinary Service
Department of Medicine 

Yoshiya (Josh) Yamada, MD
Co-Chief, Multi-Disciplinary Spine Tumor Service
Attending, External Beam Radiotherapy Service 
Department of Radiation Oncology 

Randy Yeh, MD
Associate Attending, Molecular Imaging and Therapy Service
Department of Radiology 

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.